• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疏水载脂蛋白作为临床外源性表面活性剂成分的重要性。

Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.

作者信息

Hall S B, Venkitaraman A R, Whitsett J A, Holm B A, Notter R H

机构信息

Department of Medicine, Oregon Health Sciences University, Portland 97201-3098.

出版信息

Am Rev Respir Dis. 1992 Jan;145(1):24-30. doi: 10.1164/ajrccm/145.1.24.

DOI:10.1164/ajrccm/145.1.24
PMID:1731593
Abstract

The biophysical properties and physiologic effects of a series of clinical exogenous pulmonary surfactants was compared to determine the importance of the hydrophobic apoproteins (SP-B and C) as constituents of these preparations. The three exogenous surfactants studied, calf lung surfactant extract (CLSE), Survanta (Surfactant-TA), and Exosurf, all contain dipalmitoyl phosphatidylcholine (DPPC) as their major constituent. CLSE and Survanta also contain 1 to 2% of SP-B,C but Exosurf has the additives hexadecanol and tyloxapol instead to enhance the activity of DPPC. In adsorption experiments, CLSE reached a final surface tension of 22 mN/m, and Survanta and Exosurf reached 28 and 38 mN/m, respectively. Addition of 1% by weight of an apoprotein isolate containing both SP-B and C to Exosurf slightly improved its adsorption. In oscillating bubble studies, CLSE and Survanta decreased surface tension to low values of less than 1 and 2 mN/m, respectively, but Exosurf achieved a minimum value of only 29 mN/m. Addition of SP-B,C to Exosurf improved this minimum to 1 mN/m and approached the behavior of mixtures of synthetic DPPC with SP-B,C. In both adsorption and pulsating bubble experiments, the minimum surface tensions found for Exosurf were almost identical to those generated by tyloxapol alone. In studies of physiologic activity, 20 mg of CLSE or Survanta restored the pressure-volume mechanics of lavaged, surfactant-deficient excised rat lungs to 95 and 50%, respectively, of normal prelavage levels. Instillation of Exosurf (37.5 mg) produced a minimal improvement of only 10% compared to 70% for mixtures containing 1% SP-B,C with either Exosurf or DPPC.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

比较了一系列临床外源性肺表面活性剂的生物物理特性和生理效应,以确定疏水载脂蛋白(SP-B和C)作为这些制剂成分的重要性。所研究的三种外源性表面活性剂,即小牛肺表面活性剂提取物(CLSE)、固尔苏(表面活性剂-TA)和爱全乐,均以二棕榈酰磷脂酰胆碱(DPPC)作为主要成分。CLSE和固尔苏还含有1%至2%的SP-B、C,但爱全乐含有十六醇和聚氧乙烯辛基苯基醚添加剂以增强DPPC的活性。在吸附实验中,CLSE的最终表面张力达到22 mN/m,固尔苏和爱全乐分别达到28和38 mN/m。向爱全乐中添加1%重量的同时含有SP-B和C的载脂蛋白分离物可略微改善其吸附。在振荡气泡研究中,CLSE和固尔苏分别将表面张力降低至低于1和2 mN/m的低值,但爱全乐仅达到29 mN/m的最小值。向爱全乐中添加SP-B、C可将此最小值提高至1 mN/m,并接近合成DPPC与SP-B、C混合物的行为。在吸附和脉动气泡实验中,爱全乐的最小表面张力与单独由聚氧乙烯辛基苯基醚产生的几乎相同。在生理活性研究中,20 mg的CLSE或固尔苏分别将灌洗后、表面活性剂缺乏的离体大鼠肺的压力-容积力学恢复至灌洗前正常水平的95%和50%。与含有1% SP-B、C的爱全乐或DPPC混合物的70%相比,滴注爱全乐(37.5 mg)仅产生了10%的最小改善。(摘要截断于250字)

相似文献

1
Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.疏水载脂蛋白作为临床外源性表面活性剂成分的重要性。
Am Rev Respir Dis. 1992 Jan;145(1):24-30. doi: 10.1164/ajrccm/145.1.24.
2
Susceptibility of exogenous surfactant to phospholipase A2 degradation.外源性表面活性剂对磷脂酶A2降解的敏感性。
Can J Physiol Pharmacol. 1996 Aug;74(8):957-63.
3
Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.一种抗磷脂酶的合成表面活性剂在大鼠肺中的活性及抗抑制性
Am J Respir Cell Mol Biol. 2007 Oct;37(4):387-94. doi: 10.1165/rcmb.2006-0434OC. Epub 2007 Jun 7.
4
Content of dipalmitoyl phosphatidylcholine in lung surfactant: ramifications for surface activity.肺表面活性物质中双棕榈酰磷脂酰胆碱的含量:对表面活性的影响
Pediatr Res. 1996 May;39(5):805-11. doi: 10.1203/00006450-199605000-00010.
5
Primary importance of zwitterionic over anionic phospholipids in the surface-active function of calf lung surfactant extract.两性离子磷脂在小牛肺表面活性剂提取物表面活性功能中比阴离子磷脂具有首要重要性。
Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1049-57. doi: 10.1164/ajrccm.156.4.96-10077.
6
Comparison of in vitro surface properties of clove oil-phospholipid suspensions with those of ALEC, Exosurf and Survanta.丁香酚-磷脂混悬液与ALEC、Exosurf和Survanta的体外表面性质比较。
Pulm Pharmacol Ther. 2001;14(2):85-91. doi: 10.1006/pupt.2000.0271.
7
Surface tension of therapeutic surfactants (exosurf neonatal, infasurf, and survanta) as evaluated by standard methods and criteria.通过标准方法和标准评估治疗性表面活性剂(外源性表面活性物质新生儿制剂、固尔苏和珂立苏)的表面张力。
Am J Perinatol. 1992 Sep-Nov;9(5-6):414-9. doi: 10.1055/s-2007-999278.
8
Roles of different hydrophobic constituents in the adsorption of pulmonary surfactant.不同疏水成分在肺表面活性剂吸附中的作用。
J Lipid Res. 1996 Apr;37(4):790-8.
9
Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium.
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1524-33. doi: 10.1164/ajrccm.162.4.9908104.
10
Effect of exogenous surfactant on the development of surfactant synthesis in premature rabbit lung.
Pediatr Res. 2003 Apr;53(4):671-8. doi: 10.1203/01.PDR.0000054655.95452.06. Epub 2003 Jan 15.

引用本文的文献

1
Optimizing Exogenous Surfactant as a Pulmonary Delivery Vehicle for Chicken Cathelicidin-2.优化外源性表面活性剂作为鸡 cathelicidin-2 的肺部递药载体。
Sci Rep. 2020 Jun 10;10(1):9392. doi: 10.1038/s41598-020-66448-1.
2
Effects of surfactant on propagation and rupture of a liquid plug in a tube.表面活性剂对管内液塞传播与破裂的影响。
J Fluid Mech. 2019 Aug 10;872:407-437. doi: 10.1017/jfm.2019.333. Epub 2019 Jun 10.
3
Helical side chain chemistry of a peptoid-based SP-C analogue: Balancing structural rigidity and biomimicry.
基于肽类的 SP-C 类似物的螺旋侧链化学:平衡结构刚性和仿生特性。
Biopolymers. 2019 Jun;110(6):e23277. doi: 10.1002/bip.23277. Epub 2019 Apr 10.
4
Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid:peptide lung surfactants().一种新型的抗磷脂酶二醚膦酸甘油在合成脂质-肽肺表面活性剂中的合成及活性()
Medchemcomm. 2011 Dec 1;2(12):1167-1173. doi: 10.1039/C1MD00206F. Epub 2011 Oct 19.
5
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
6
Pulmonary surfactant proteins and polymer combinations reduce surfactant inhibition by serum.肺表面活性物质蛋白与聚合物组合可减少血清对表面活性物质的抑制作用。
Biochim Biophys Acta. 2011 Oct;1808(10):2366-73. doi: 10.1016/j.bbamem.2011.06.013. Epub 2011 Jun 27.
7
Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches.急性呼吸窘迫综合征的预防和治疗的药物治疗:当前和实验方法。
Drugs. 2010 Jul 9;70(10):1255-82. doi: 10.2165/10898570-000000000-00000.
8
Close mimicry of lung surfactant protein B by "clicked" dimers of helical, cationic peptoids.通过“点击”二聚体的螺旋状、阳离子类肽模拟肺表面活性蛋白 B。
Biopolymers. 2009;92(6):538-53. doi: 10.1002/bip.21309.
9
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.急性肺损伤和急性呼吸窘迫综合征的药物治疗
Curr Med Chem. 2008;15(19):1911-24. doi: 10.2174/092986708785132942.
10
The biophysical function of pulmonary surfactant.肺表面活性物质的生物物理功能。
Respir Physiol Neurobiol. 2008 Nov 30;163(1-3):244-55. doi: 10.1016/j.resp.2008.05.018. Epub 2008 Jul 16.